340 The Epi-RTM technology produces a polyclonal TIL product (LYL845) with diverse tumor-reactive clones that have stem-like qualities and anti-tumor function

Abstract

BackgroundAdoptive cell therapy using tumor-infiltrating lymphocytes (TIL) is a promising method for cancer treatment. Unlike other cell therapies that engineer the tumor-targeting receptor into the T cells, TIL therapy preserves...